Selective internal radiation therapy for liver metastases from colorectal cancer
- 7 October 2009
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2009 (4) , CD007045
Abstract
Liver metastases are often the dominant site of metastatic disease in colorectal cancer. Selective internal radiation therapy (SIRT) involves embolising radiolabeled spheres (SIR‐Spheres) into the arterial supply of the liver with the aim of improving the control of liver metastases. To assess the effectiveness and toxicity of SIRT in the treatment of metastatic colorectal cancer liver metastasis when given alone or with systemic or regional hepatic artery chemotherapy. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane library 2008 issue 2, MEDLINE (1966 to October 2008), EMBASE (1980 to October 2008), and Pubmed (October 2008). The proceedings of ASCO (1985 to 2008) and ASCO GI (2004 to 2008) were also searched. The manufacturers of SIR‐Spheres were contacted and asked whether they were aware of any other unpublished studies. Randomised controlled trials comparing SIRT and chemotherapy (systemic and/or regional) with chemotherapy alone, or comparing SIRT alone with best supportive care in patients with metastatic colorectal cancer. Two authors (AT/TP) extracted data and assessed the trial quality. The study authors were contacted and individual patient data was obtained. Results were analysed separately for patients with and without extra‐hepatic disease. A single study of 21 patients compared SIRT and systemic chemotherapy (fluorouracil and leucovorin) with chemotherapy alone. There was a significant improvement in progression free survival and median survival associated with SIRT, both for the total studied population and for those disease limited to the liver. There was an increase in toxicity with the use of SIRT. A second study of 63 eligible patients compared SIRT and regional chemotherapy (floxuridine) with regional chemotherapy alone. There was no significant difference in progression free survival and median survival seen with SIRT, in either the total patient group or in the 22 patients with disease limited to the liver. There was no significant increase in toxicity with the addition of SIRT to regional chemotherapy. There were no randomised studies comparing SIRT with best supportive care in patients with refractory disease, and no randomised studies assessing the effect of SIRT in patients with resectable liver metastases. There is a need for well designed, adequately powered phase III trials assessing the effect of SIRT when used with modern combination chemotherapy regimens. Further studies are also needed for patients with refractory disease with a particular focus on the impact on quality of life. 利用選擇性體內放射線治療法(Selective internal radiation therapy)來治療由大腸直腸移轉至肝臟的癌細胞 肝臟轉移通常是大腸直腸癌轉移的主要轉移結果,選擇性體內放射線治療法(Selective internal radiation therapy,SIRT)是將帶有放射線的球體(SIRPgheres)的管子插入肝臟動脈中,以提升對於肝臟移轉的控制效果 本研究的主要目的在於評估將SIRT單獨使用和與全身性或區域性肝臟動脈治療法併用時,對於移轉性大腸直腸癌的肝臟移轉治療功效及毒性, 我們檢索了Cochrane Central Register of Controlled Trials (CENTRAL)、Cochrane library 2008年第2期, MEDLINE (1966年至2008年10月), EMBASE (1980 年至2008年10月)和Pubmed (2008年10月)資料庫,也調閱了ASCO (1985 至 2008) 和ASCO GI (2004至2008)的會議記錄,並且聯繫SIRspheres的製造商以詢問其是否有發現任何其他未公開的研究資訊 比較SIRT和化學治療法(全身性和局部性)併用和單獨使用化學治療法的治療效果的隨機性對照試驗會被納入本研究中,另外,比較單獨使用SIRT和最佳支持性照護對移轉性大腸直腸癌患者影響的隨機性對照試驗也會被納入研究中 有2位作者(AT/TP)會進行資料萃取及評估試驗品質的工作,並聯繫試驗作者以取得個別患者的數據,根據患者有沒有患有其他肝臟疾病來將數據進行分別的分析 有1個納入21位患者的試驗係比較SIRT和全身性化學治療(使用fluorouracil和leucovorin藥物)併用以及單獨進行化學治療的影響,搭配使用SIRT可以使患者的無惡化存活率和中期存活率明顯提升,這樣的結果適用於所有的試驗患者,也適用於那些限定有肝臟疾病的患者,在使用SIRT時會出現毒性增加的現象,有一個針對63名適當患者進行的試驗係比較使用SIRT併行局部性化學治療(使用floxuridine藥劑)和單獨進行局部性化學治療的效果,對於有接受SIRT治療的患者來說,在全體受試病患和22個患有肝臟疾病的病患身上,其無惡化存活率和中期存活率並沒有明顯的變化, 將SIRT併行局部性化學治療也沒有出現明顯的毒性增加情形,目前並沒有比較SIRT和支持性照護對於患有不易治癒疾病(refractory disease)治療效果的隨機性試驗,也沒有試驗評估SIRT對於可以接受切除治療的肝臟轉移患者的影響 基於上述結果,還需要更多具有良好試驗設計及適當效力第三期試驗,來評估使用SIRT和現行併用的化學性治療療程的影響,也需要更多的試驗針對那些患有不易治癒的患者,瞭解SIRT治療對於其生活品質的影響 本摘要由臺中榮民總醫院薛榮華翻譯 此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌...This publication has 15 references indexed in Scilit:
- FOXFIRE: A Phase III Clinical Trial of Chemo-radio-embolisation as First-line Treatment of Liver Metastases in Patients with Colorectal CancerClinical Oncology, 2008
- Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin ChemotherapyJournal of Clinical Oncology, 2007
- Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignanciesInternal Medicine Journal, 2005
- Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741Annals of Oncology, 2005
- Randomised phase 2 trial of SIR‐Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancerJournal of Surgical Oncology, 2004
- Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by ChemotherapyAnnals of Surgery, 2004
- Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of TreatmentJournal of Clinical Oncology, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.BMJ, 1993